Review of natural products actions on cytokines in inflammatory bowel disease

Nutrition Research

Volumn 32, Issue 11, 2012, Pages 801-816

  Hur, Sun Jin ^a   Kang, Sung Ho ^b   Jung, Ho Sung ^b   Kim, Sang Chul ^b   Jeon, Hyun Soo ^b   Kim, Ick Hee ^b   Lee, Jae Dong ^b  

^a Konkuk University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Cytokine; Inflammatory bowel disease; Natural products; Phytochemicals; Probiotics

Indexed keywords

ANTIOXIDANT; CODIUM FRAGILE EXTRACT; CONJUGATED LINOLEIC ACID; COPAIFERA LANGSDORFFI EXTRACT; CURCUMIN; EPOXYICOSATRIENOIC ACID; FLAVONOID; GREEN TEA EXTRACT; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INORGANIC COMPOUND; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LACTIC ACID; LIPID; MYELOPEROXIDE; NATURAL PRODUCT; NITRIC OXIDE; NUCLEAR FACTOR KAPPA LIGHT CHAIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; POLYPHENOL; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RUTOSIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; B LYMPHOCYTE; BACTERIUM; CODIUM FRAGILE; COLITIS; COPAIFERA LANGSDORFFI; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DEGENERATIVE DISEASE; DIETARY FIBER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; LACTOBACILLUS RHAMNOSUS; LYMPHOCYTE ACTIVATION; MEDICINAL PLANT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS;

BIOLOGICAL AGENTS; CYTOKINES; DIETARY FIBER; FATTY ACIDS, OMEGA-3; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; POLYPHENOLS; PROBIOTICS;

BACTERIA (MICROORGANISMS);

EID: 84870061077     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.09.013     Document Type: Review

References (164)

1. Sanchez-Muñoz F., Dominguez-Lopez A., Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008, 14:4280-4288.
2. Ueda Y., Kawakami Y., Kunii D., Okada H., et al. Elevated concentrations of linoleic acid in erythrocyte membrane phospholipids in patients with inflammatory bowel disease. Nutr Res 2008, 28:239-244.
3. Ardizzone S., Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005, 65:2253-2286.
4. Cho E.-J., Shin J.-S., Noh Y.-S., Cho Y.-W., et al. Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis. J Ethnopharmacol 2011, 136:428-435.
5. Sergent T., Piront N., Meurice J., Toussaint O., Schneider Y.-J. Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. Chem Biol Interact 2010, 188:659-667.
6. García-Lafuente A., Guillamón E., Villares A., Rostagno M., Martínez J. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res 2009, 58:537-552.
7. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006, 72:1439-1452.
8. Koretz R.L., Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004, 2:957-967.
9. da Silva M.S., Sánchez-Fidalgo S., Talero E., Cárdeno A., et al. Anti-inflammatory intestinal activity of Abarema cochliacarpos (Gomes) Barneby & Grimes in TNBS colitis model. J Ethnopharmacol 2010, 128:467-475.
10. Chen H.-J., Chung C.-P., Chiang W., Lin Y.-L. Anti-inflammatory effects and chemical study of a flavonoid-enriched fraction from adlay bran. Food Chem 2011, 126:1741-1748.
11. Mandalari G., Bisignano C., Genovese T., Mazzon E., et al. Natural almond skin reduced oxidative stress and inflammation in an experimental model of inflammatory bowel disease. Int Immunopharmacol 2011, 11:915-924.
12. Park M.-Y., Kwon H.-J., Sung M.-K. Dietary aloin, aloesin, or aloe-gel exerts anti-inflammatory activity in a rat colitis model. Life Sci 2011, 88:486-492.
13. Oz H.S., Chen T.S., McClain C.J., de Villiers W.J.S. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem 2005, 16:297-304.
14. Yoshioka Y., Akiyama H., Nakano M., Shoji T., et al. Orally administered apple procyanidins protect against experimental inflammatory bowel disease in mice. Int Immunopharmacol 2008, 8:1802-1807.
15. D'Argenio G., Mazzone G., Tuccillo C., Ribecco M.T., et al. Apple polyphenols extract (APE) improves colon damage in a rat model of colitis. Dig Liver Dis 2012, 44:555-562.
16. Ko J.K.-S., Chik C.W.-S. The protective action of radix Astragalus membranaceus against hapten-induced colitis through modulation of cytokines. Cytokine 2009, 47:85-90.
17. Maity S., Ukil A., Karmakar S., Datta N., et al. Thearubigin, the major polyphenol of black tea, ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. Eur J Pharmacol 2003, 470:103-112.
18. Jagtap A.G., Niphadkar P.V., Phadke A.S. Protective effect of aqueous extract of Bombax malabaricum DC on experimental models of inflammatory bowel disease in rats and mice. Indian J Exp Biol 2011, 49:343-351.
19. Gayathri B., Manjula N., Vinaykumar K.S., Lakshmi B.S., Balakrishnan A. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. Int Immunopharmacol 2007, 7:473-482.
20. Cheon M.S., Yoon T., Lee D.Y., Choi G., et al. Chrysanthemum indicum Linné extract inhibits the inflammatory response by suppressing NF-κB and MAPKs activation in lipopolysaccharide-induced RAW 2647 macrophages. J Ethnopharmacol 2009, 122:473-477.
21. Kang C.-H., Choi Y.H., Park S.-Y., Kim G.-Y. Anti-inflammatory effects of methanol extract of Codium fragile in lipopolysaccharide-stimulated RAW 264.7 cells. J Med Food 2012, 15:44-50.
22. Paiva L.A.F., Gurgel L.A., Silva R.M., Tomé A.R., et al. Anti-inflammatory effect of kaurenoic acid, a diterpene from Copaifera langsdorffii on acetic acid-induced colitis in rats. Vascul Pharmacol 2002, 39:303-307.
23. Han E.S., Oh J.Y., Park H.-J. Cordyceps militaris extract suppresses dextran sodium sulfate-induced acute colitis in mice and production of inflammatory mediators from macrophages and mast cells. J Ethnopharmacol 2011, 134:703-710.
24. Seo W.-G., Pae H.-O., Oh G.-S., Chai K.-Y., et al. Inhibitory effects of methanol extract of Cyperus rotundus rhizomes on nitric oxide and superoxide productions by murine macrophage cell line, RAW 264.7 cells. J Ethnopharmacol 2001, 76:59-64.
25. Sugimoto K., Sakamoto S., Nakagawa K., Hayashi S., et al. Suppression of inducible nitric oxide synthase expression and amelioration of lipopolysaccharide-induced liver injury by polyphenolic compounds in Eucalyptus globulus leaf extract. Food Chem 2011, 125:442-446.
26. Liu X., Wang J. Anti-inflammatory effects of iridoid glycosides fraction of Folium syringae leaves on TNBS-induced colitis in rats. J Ethnopharmacol 2011, 133:780-787.
27. El-Abhar H.S., Hammad L.N.A., Gawad H.S.A. Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol 2008, 118:367-372.
28. Zhou Y.-H., Yu J.-P., Liu Y.-F., Teng X.-J., et al. Effect of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-α, NF-[U+049B]Bp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 2006, 2006:1-9.
29. Abboud P.A., Hake P.W., Burroughs T.J., Odoms K., et al. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharm 2008, 579:411-417.
30. Park M.-Y., Ji G., Sung M.-K. Dietary kaempferol suppresses inflammation of dextran sulfate sodium-induced colitis in mice. Dig Dis Sci 2012, 57:355-363.
31. Edmunds S.J., Roy N.C., Love D.R., Laing W.A. Kiwifruit extracts inhibit cytokine production by lipopolysaccharide-activated macrophages, and intestinal epithelial cells isolated from IL10 gene deficient mice. Cell Immunol 2011, 270:70-79.
32. Seo H.-J., Huh J.-E., Han J.-H., Jeong S.-J., et al. Polygoni Rhizoma inhibits inflammatory response through inactivation of nuclear factor-kappaB and mitogen activated protein kinase signaling pathways in RAW264.7 mouse macrophage cells. Phytother Res 2012, 26:239-245.
33. Jagtap A.G., Shirke S.S., Phadke A.S. Effect of polyherbal formulation on experimental models of inflammatory bowel diseases. J Ethnopharmacol 2004, 90:195-204.
34. Romier-Crouzet B., Van De Walle J., During A., Joly A., et al. Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol 2009, 47:1221-1230.
35. Larrosa M., González-Sarrías A., Yáñez-Gascón M.J., Selma M.V., et al. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 2010, 21:717-725.
36. Kazłowska K., Hsu T., Hou C.-C., Yang W.-C., Tsai G.-J. Anti-inflammatory properties of phenolic compounds and crude extract from Porphyra dentata. J Ethnopharmacol 2010, 128:123-130.
37. Kim J.-K., Oh S.-M., Kwon H.-S., Oh Y.-S., et al. Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biochem Biophys Res Commun 2006, 345:1215-1223.
38. Kwon K.H., Murakami A., Hayashi R., Ohigashi H. Interleukin-1β targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. Biochem Biophys Res Commun 2005, 337:647-654.
39. Young D., Ibuki M., Nakamori T., Fan M., Mine Y. Soy-derived di- and tripeptides alleviate colon and ileum inflammation in pigs with dextran sodium sulfate-induced colitis. J Nutr 2012, 142:363-368.
40. Bassaganya-Riera J., Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006, 25:454-465.
41. Bassaganya-Riera J., Reynolds K., Martino-Catt S., Cui Y., et al. Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004, 127:777-791.
42. Evans N.P., Misyak S.A., Schmelz E.M., Guri A.J., et al. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARγ. J Nutr 2010, 140:515-521.
43. Reynolds C.M., Loscher C.E., Moloney A.P., Roche H.M. Cis-9, trans-11-conjugated linoleic acid but not its precursor trans-vaccenic acid attenuate inflammatory markers in the human colonic epithelial cell line Caco-2. Br J Nutr 2008, 100:13-17.
44. Lee Y., Thompson J.T., Vanden Heuvel J.P. 9E,11E-conjugated linoleic acid increases expression of the endogenous antiinflammatory factor, interleukin-1 receptor antagonist, in RAW 264.7 cells. J Nutr 2009, 139:1861-1866.
45. Wall R., Ross R.P., Fitzgerald G.F., Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 2010, 68:280-289.
46. Sierra S., Lara-Villoslada F., Comalada M., Olivares M., Xaus J. Dietary fish oil n-3 fatty acids increase regulatory cytokine production and exert anti-inflammatory effects in two murine models of inflammation. Lipids 2006, 41:1115-1125.
47. Kono H., Fujii H., Ogiku M., Tsuchiya M., et al. Enteral diets enriched with medium-chain triglycerides and N-3 fatty acids prevent chemically induced experimental colitis in rats. Transl Res 2010, 156:282-291.
48. Ibrahim A., Mbodji K., Hassan A., Aziz M., et al. Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr 2011, 30:678-687.
49. Li Q., Zhang Q., Wang M., Zhao S., et al. n-3 polyunsaturated fatty acids prevent disruption of epithelial barrier function induced by proinflammatory cytokines. Mol Immunol 2008, 45:1356-1365.
50. Whiting C.V., Bland P.W., Tarlton J.F. Dietary n-3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis. Inflamm Bowel Dis 2005, 11:340-349.
51. Borniquel S., Jansson E.Å., Cole M.P., Freeman B.A., Lundberg J.O. Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease. Free Radic Biol Med 2010, 48:499-505.
52. Camuesco D., Comalada M., Concha A., Nieto A., et al. Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin Nutr 2006, 25:466-476.
53. Tedelind S., Westberg F., Kjerrulf M., Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007, 28:2826-2832.
54. Serpe L., Canaparo R., Daperno M., Sostegni R., et al. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. Eur J Pharm Sci 2010, 39:428-436.
55. Hao W., Wong O.Y., Liu X., Lee P., et al. ω-3 fatty acids suppress inflammatory cytokine production by macrophages and hepatocytes. J Pediatr Surg 2010, 45:2412-2418.
56. Schubert R., Kitz R., Beermann C., Rose M.A., et al. Influence of low-dose polyunsaturated fatty acids supplementation on the inflammatory response of healthy adults. Nutrition 2007, 23:724-730.
57. McNamara R.K., Jandacek R., Rider T., Tso P., et al. Omega-3 fatty acid deficiency increases constitutive pro-inflammatory cytokine production in rats: relationship with central serotonin turnover. Prostaglandins Leukot Essent Fatty Acids 2010, 83:185-191.
58. Ibrahim A., Aziz M., Hassan A., Mbodji K., et al. Dietary α-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition 2012, 28:799-802.
59. Ohtsuka Y., Okada K., Yamakawa Y., Ikuse T., et al. ω-3 fatty acids attenuate mucosal inflammation in premature rat pups. J Pediatr Surg 2011, 46:489-495.
60. Grimstad T., Bjørndal B., Cacabelos D., Aasprong O.G., et al. Dietary supplementation of krill oil attenuates inflammation and oxidative stress in experimental ulcerative colitis in rats. Scand J Gastroenterol 2012, 47:49-58.
61. Frias R., Ouwehand A., Spillmann T., Vankerckhoven V., et al. Effect of clinical and probiotic Lactobacillus rhamnosus strains on intestinal permeability and bacterial translocation in healthy and colitic rats. Food Res Int 2009, 42:636-640.
62. Pena J.A., Rogers A.B., Ge Z., Ng V., et al. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun 2005, 73:912-920.
63. Peran L., Camuesco D., Comalada M., Bailon E., et al. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J Appl Microbiol 2007, 103:836-844.
64. Schultz M., Veltkamp C., Dieleman L.A., Grenther W.B., et al. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis 2002, 8:71-80.
65. Madsen K., Cornish A., Soper P., McKaigney C., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
66. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
67. Imaoka A., Shima T., Kato K., Mizuno S., et al. Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol 2008, 28:2511-2516.
68. Drouault-Holowacz S., Foligné B., Dennin V., Goudercourt D., et al. Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: in vitro and in vivo considerations. Clin Nutr 2006, 25:994-1003.
69. Abdin A.A., Saeid E.M. An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without "olsalazine". J Crohns Colitis 2008, 2:296-303.
70. Lorea Baroja M., Kirjavainen P.V., Hekmat S., Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol 2007, 149:470-479.
71. Herías M.V., Koninkx J.F.J.G., Vos J.G., Huis in't Veld J.H.J., van Dijk J.E. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int J Food Microbiol 2005, 103:143-155.
72. Dalmasso G., Cottrez F., Imbert V., Lagadec P., et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006, 131:1812-1825.
73. Matsumoto S., Hara T., Hori T., Mitsuyama K., et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005, 140:417-426.
74. O'Mahony L., Feeney M., O'Halloran S., Murphy L., et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001, 15:1219-1225.
75. Khokhlova E.V., Smeianov V.V., Efimov B.A., Kafarskaia L.I., et al. Anti-inflammatory properties of intestinal Bifidobacterium strains isolated from healthy infants. Microbiol Immunol 2012, 56:27-39.
76. Takata K., Kinoshita M., Okuno T., Moriya M., et al. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. PLoS One 2011, 6:e27644.
77. Xia Y., Chen H.-Q., Zhang M., Jiang Y.-Q., et al. Effect of Lactobacillus plantarum LP-Onlly on gut flora and colitis in interleukin-10 knockout mice. J Gastroenterol Hepatol 2011, 26:405-411.
78. Sabit H., Farouk A., Said O., Yehia M., Bishr A. Molecular characterization of Bifidobacteria and Lactobacillus and their role in modulating immune system and alleviating ulcerative colitis in mice. Global J Mol Sci 2011, 6:9-14.
79. Duary R., Bhausaheb M., Batish V., Grover S. Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model. Mol Biol Rep 2012, 39:4765-4775.
80. Rodríguez-Cabezas M.E., Gálvez J., Camuesco D., Lorente M.D., et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr 2003, 22:463-471.
81. Bassaganya-Riera J., DiGuardo M., Viladomiu M., de Horna A., Sanchez S., Einerhand A.W., et al. Soluble fibers and resistant starch ameliorate disease activity in interleukin-10-deficient mice with inflammatory bowel disease. J Nutr 2011, 141:1318-1325.
82. Magri L.D.P., Batista L.M., Almeida A.B.A., Farias-Silva E., et al. Dietary fibers prevent ethanol and nonsteroidal anti-inflammatory drug-induced gastric mucosal damage in rats. Nutr Res 2007, 27:109-112.
83. Kanauchi O., Iwanaga T., Andoh A., Araki Y., et al. Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. J Gastroenterol Hepatol 2001, 16:160-168.
84. Rose D.J., DeMeo M.T., Keshavarzian A., Hamaker B.R. Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern. Nutr Rev 2007, 65:51-62.
85. Lim B.O., Lee S.H., Park D.K., Choue R.W. Effect of dietary pectin on the production of immunoglobulins and cytokines by mesenteric lymph node lymphocytes in mouse colitis induced with dextran sulfate sodium. Biosci Biotechnol Biochem 2003, 67:1706-1712.
86. Ye M.B., Lim B.O. Dietary pectin regulates the levels of inflammatory cytokines and immunoglobulins in interleukin-10 knockout mice. J Agric Food Chem 2010, 58:11281-11286.
87. Pouillart P.R., Dépeint F., Abdelnour A., Deremaux L., et al. Nutriose, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets. Inflamm Bowel Dis 2010, 16:783-794.
88. Faghfoori Z., Navai L., Shakerhosseini R., Somi M.H., et al. Effects of an oral supplementation of germinated barley foodstuff on serum tumour necrosis factor-α, interleukin-6 and -8 in patients with ulcerative colitis. Ann Clin Biochem 2011, 48:233-237.
89. Komiyama Y., Andoh A., Fujiwara D., Ohmae H., et al. New prebiotics from rice bran ameliorate inflammation in murine colitis models through the modulation of intestinal homeostasis and the mucosal immune system. Scand J Gastroenterol 2011, 46:40-52.
90. Komiyama Y., Mitsuyama K., Masuda J., Yamasaki H., et al. Prebiotic treatment in experimental colitis reduces the risk of colitic cancer. J Gastroenterol Hepatol 2011, 26:1298-1308.
91. Azuma K., Osaki T., Wakuda T., Ifuku S., et al. Beneficial and preventive effect of chitin nanofibrils in a dextran sulfate sodium-induced acute ulcerative colitis model. Carbohydr Polym 2012, 87:1399-1403.
92. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ. J Exp Med 2005, 201:1205-1215.
93. Desreumaux P., Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 2006, 24:2-9.
94. Horváth K., Varga C., Berkó A., Pósa A., et al. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur J Pharmacol 2008, 581:315-323.
95. Tozaki H., Odoriba T., Okada N., Fujita T., et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release 2002, 82:51-61.
96. Pertuit D., Moulari B., Betz T., Nadaradjane A., et al. 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Release 2007, 123:211-218.
97. Brown J.B., Lee G., Managlia E., Grimm G.R., et al. Mesalamine inhibits epithelial β-catenin activation in chronic ulcerative colitis. Gastroenterology 2010, 138:595-605.e593.
98. Mura C., Nácher A., Merino V., Merino-Sanjuan M., et al. N-succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats. Int J Pharm 2011, 416:145-154.
99. Ancha H.R., Kurella R.R., McKimmey C.C., Lightfoot S., HartY R.F. Luminal antioxidants enhance the effects of mesalamine in the treatment of chemically induced colitis in rats. Exp Biol Med 2008, 233:1301-1308.
100. Leung D.Y.M., Bloom J.W. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003, 111:3-22.
101. Joo K., Lee Y., Choi D., Han J., et al. An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1β-mediated NFκB activation. Eur J Pharmacol 2009, 618:91-97.
102. Bautzová T., Rabišková M., Béduneau A., Pellequer Y., Lamprechtr A. Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis. Eur J Pharm Biopharm 2012, 81:379-385.
103. Aguzzi C., Ortega A., Bonferoni M.C., Sandri G., et al. Assessement of anti-inflammatory properties of microspheres prepared with chitosan and 5-amino salicylic acid over inflamed Caco-2 cells. Carbohydr Polym 2011, 85:638-644.
104. Gorgulu S., Yagci G., Kaymakcioglu N., Özkara M., et al. Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci 2006, 51:480-487.
105. Dhaneshwar S.S., Chail M., Patil M., Naqvi S., Vadnerkar G. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur J Med Chem 2009, 44:131-142.
106. Stolfi C., Fina D., Caruso R., Caprioli F., et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008, 75:668-676.
107. Manuela G.N. Immune dysfunction in inflammatory bowel disease. Transl Res 2007, 149:173-186.
108. Dionne S., D'Agata D.D., Hiscott J., Vanounou T., Seidman E.G. Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998, 112:435-442.
109. Malek R., Borowicz K.K., Jargiello M., Czuczwar S.J. Role of nuclear factor B in the central nervous system. Pharmacol Rep 2007, 59:25-33.
110. Zhang D., Cheng L., Huang X., Shi W., et al. Tetrandrine ameliorates dextran-sulfate-sodium-induced colitis in mice through inhibition of nuclear factor-κB activation. Int J Colorectal Dis 2009, 24:5-12.
111. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996, 9:998-1004.
112. Atreya R., Neurath M.F. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 2008, 1:175-182.
113. An M.J., Cheon J.H., Kim S.W., Park J.J., et al. Bovine colostrum inhibits nuclear factor κB-mediated proinflammatory cytokine expression in intestinal epithelial cells. Nutr Res 2009, 29:275-280.
114. Park Y.-K., Rasmussen H.E., Ehlers S.J., Blobaum K.R., et al. Repression of proinflammatory gene expression by lipid extract of Nostoc commune var sphaeroides Kützing, a blue-green alga, via inhibition of nuclear factor-κB in RAW 264.7 macrophages. Nutr Res 2008, 28:83-91.
115. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B., Haegerman G. A paradigm for gene regulation: Inflammation, NF-kappaB and PPAR. Adv Exp Med Biol 2003, 544:181-196.
116. Talero E., Sánchez-Fidalgo S., de la Lastra C.A., Illanes M., et al. Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides 2008, 29:2001-2012.
117. Roy P.K., Rashid F., Bragg J., Ibdah J.A. Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol 2008, 14:200-202.
118. Mora A., Payá M., Ríos J.L., Alcaraz M.J. Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation. Biochem Pharmacol 1990, 40:793-797.
119. Erlund I., Kosonen T., Alfthan G., Mäenpää J., et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 2000, 56:545-553.
120. Gálvez J., Cruz T., Crespo E., Ocete M.A., et al. Rutoside as mucosal protective in acetic acid-induced rat colitis. Planta Med 1997, 63:409,414.
121. Dryden G.W., Song M., McClain C. Polyphenols and gastrointestinal diseases. Curr Opin Gastroenterol 2006, 22:165-170. [110.1097/1001.mog.0000208463.0000269266.0000208468c].
122. Soobrattee M.A., Neergheen V.S., Luximon-Ramma A., Aruoma O.I., Bahorun T. Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat Res/Fundam Mol Mech Mutagen 2005, 579:200-213.
123. Yang F., Oz H.S., Barve S., de Villiers W.J.S., et al. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-κB activation by inhibiting IκB kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001, 60:528-533.
124. Ran Z.H., Chen C., Xiao S.D. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed Pharmacother 2008, 62:189-196.
125. Lu J., Ho C.-T., Ghai G., Chen K.Y. Differential effects of theaflavin monogallates on cell growth, apoptosis, and Cox-2 gene expression in cancerous versus normal cells. Cancer Res 2000, 60:6465-6471.
126. Peng G., Dixon D.A., Muga S.J., Smith T.J., Wargovich M.J. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. Mol Carcinog 2006, 45:309-319.
127. Lin Y.-L., Lin J.-K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB. Mol Pharmacol 1997, 52:465-472.
128. Bengmark S. Bioecological control of inflammatory bowel disease. Clin Nutr 2007, 26:169-181.
129. Park J.-Y., Kawada T., Han I.-S., Kim B.-S., et al. Capsaicin inhibits the production of tumor necrosis factor α by LPS-stimulated murine macrophages, RAW 264.7: a PPARγ ligand-like action as a novel mechanism. FEBS Lett 2004, 572:266-270.
130. Kruidenier L., Verspaget H.W. Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous?. Aliment Pharmacol Ther 2002, 16:1997-2015.
131. Cross R.K., Wilson K.T. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 2003, 9:179-189.
132. Beckman K.B., Ames B.N. Oxidative decay of DNA. J Biol Chem 1997, 272:19633-19636.
133. Shiratora Y., Aoki S., Takada H., Kiriyama H., et al. Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 1989, 44:163-171.
134. Islam M.S., Murata T., Fujisawa M., Nagasaka R., et al. Anti-inflammatory effects of phytosteryl ferulates in colitis induced by dextran sulphate sodium in mice. Br J Pharmacol 2008, 154:812-824.
135. Mårtensson J., Jain A., Meister A. Glutathione is required for intestinal function. Proc Natl Acad Sci 1990, 87:1715-1719.
136. Khan S.G., Katiyar S.K., Agarwal R., Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res 1992, 52:4050-4052.
137. Martindale-the complete drug reference 1999, 1199. Pharmaceutical Press, United Kingdom. 32nd ed. K. Parfitt (Ed.).
138. Nobilis M., Vybíralová Z., Sládková K., Lísa M., et al. High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. J Chromatogr A 2006, 1119:299-308.
139. Lakhan S., Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 2010, 7:37.
140. Paul G., Bataille F., Obermeier F., Bock J., Klebl F., Strauch U., et al. Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. Clin Exp Immunol 2005, 140:547-555.
141. Sanovic S., Lamb D., Blennerghassett M. Damage to the enteric nervous system in experimental colitis. Am J Pathol 1999, 155:1051-1057.
142. Collier-Hyams L., Neish A. Intestinal epithelial barrier and mucosal immunity. Cell Mol Life Sci 2005, 62:1339-1348.
143. Fellermann K., Wehkamp J., Herrlinger K.R., Stange E.F. Crohn's disease: a defensin deficiency syndrome?. Eur J Gastroenterol Hepatol 2003, 15:627-634.
144. Yan F., Polk D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002, 277:50959-50965.
145. Candela M., Perna F., Carnevali P., Vitali B., et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 2008, 125:286-292.
146. Geier M.S., Butler R.N., Howarth G.S. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007, 115:1-11.
147. LeBlanc J., Carmen S.D., Miyoshi A., Azevedo V., et al. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. J Biotechnol 2011, 15:287-293.
148. Hendrickson B., Gokhale R., Cho J. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002, 79-94.
149. Hyun J., Mayer L. Mechanisms underlying inflammatory bowel disease. Drug Discov Today Dis Mech 2006, 3:457-462.
150. Neuman M., Nanau R. Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 2012, 160:29-44.
151. DeVroey B., Cassan C.D., Gower-Rousseau C., Colombel J. Editorial: antibiotics earlier, IBD later?. Am J Gastroenterol 2010, 105:2693-2696.
152. Koretz R.L. Immunonutrition: can you be what you eat?. Curr Opin Gastroenterol 2003, 19:134-139.
153. Esteve-Comas M., Ramírez M., Fernández-Bañares F., Abad-Lacruz A., et al. Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut 1992, 33:1365-1369.
154. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000, 192:1197-1204.
155. Lewis R.A., Austen K.F., Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990, 323:645-655.
156. Calder P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res 2008, 52:885-897.
157. Andersen V., Olsen A., Carbonnel F., Tjønneland A., Vogel U. Diet and risk of inflammatory bowel disease. Dig Liver Dis 2012, 44:185-194.
158. Shoda R., Matsueda K., Yamato S., Umeda N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 1996, 63:741-745.
159. Alzoghaibi M.A., Walsh S.W., Willey A., Fowler Iii A.A., Graham M.F. Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin Nutr 2003, 22:529-535.
160. Shores D., Binion D., Freeman B., Baker P. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:2192-2204.
161. Zhao G., Etherton T., Martin K., West S., et al. Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 2004, 134:2291-2297.
162. Magee P., Pearson S., Whittingham-Dowd J., Allen J. PPARγ as a molecular target of EPA anti-inflammatory activity during TNF-α-impaired skeletal muscle cell differentiation. J Nutr Biochem 2012, [in press].
163. Kawashima A., Harada T., Imada K., Yano T., Mizuguchi K. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostag Leukot Essent Fatty Acids 2008, 79:59-65.
164. Draper E., Reynolds C., Canavan M., Mills K., et al. Omega-3 fatty acids attenuate dendritic cell function via NF-kappaB independent of PPARgamma. J Nutr Biochem 2011, 22:784-790.